Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexien BioPharma's EPS (Basic) for the
three
months ended in Mar. 2025 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.00.
Nexien BioPharma (OTCPK:NXEN) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Nexien BioPharma Earnings per Share (Diluted) Related Terms
Nexien BioPharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Nexien BioPharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexien BioPharma Earnings per Share (Diluted) Chart
NXEN vs FLHLF, ZTS, UTHR: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexien BioPharma PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Nexien BioPharma's PE Ratio falls into.
Nexien BioPharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Nexien BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.00 mean?
Nexien BioPharma (NXEN) has a Earnings per Share (Diluted) of $-0.00 as of Mar. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Nexien BioPharma and its competitors.
Is Nexien BioPharma's Earnings per Share (Diluted) too high?
Nexien BioPharma's current Earnings per Share (Diluted) is $-0.00.
How does Nexien BioPharma's Earnings per Share (Diluted) compare to FLHLF and ZTS?
Nexien BioPharma's Earnings per Share (Diluted) of $-0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Earnings per Share (Diluted) is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Nexien BioPharma and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexien BioPharma's current Earnings per Share (Diluted) is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexien BioPharma stock overvalued right now?
Nexien BioPharma (NXEN) has a current Earnings per Share (Diluted) of $-0.00. The current Earnings per Share (Diluted) is $-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Nexien BioPharma (NXEN), the current Earnings per Share (Diluted) is $-0.00 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nexien BioPharma Inc is engaged in pre-clinical and drug development activities, by U.S. Food and Drug Administration (FDA) protocols, for certain pharmaceutical formulations that include cannabinoids. The company is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders, and medical conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXEN has been successfully added to your 
